- Home
- ATHA vs MITQ Comparison
ATHA vs MITQ Comparison
Compare ATHA & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- MITQ
- Stock Information
- Founded
- ATHA 2011
- MITQ N/A
- Country
- ATHA United States
- MITQ United States
- Employees
- ATHA N/A
- MITQ N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- MITQ Telecommunications Equipment
- Sector
- ATHA Health Care
- MITQ Telecommunications
- Exchange
- ATHA Nasdaq
- MITQ Nasdaq
- Market Cap
- ATHA 14.8M
- MITQ 13.4M
- IPO Year
- ATHA 2020
- MITQ 2021
- Fundamental
- Price
- ATHA $3.82
- MITQ $0.85
- Analyst Decision
- ATHA
- MITQ
- Analyst Count
- ATHA 0
- MITQ 0
- Target Price
- ATHA N/A
- MITQ N/A
- AVG Volume (30 Days)
- ATHA 48.3K
- MITQ 225.8K
- Earning Date
- ATHA 11-06-2025
- MITQ 11-13-2025
- Dividend Yield
- ATHA N/A
- MITQ N/A
- EPS Growth
- ATHA N/A
- MITQ N/A
- EPS
- ATHA N/A
- MITQ N/A
- Revenue
- ATHA N/A
- MITQ $18,147,000.00
- Revenue This Year
- ATHA N/A
- MITQ N/A
- Revenue Next Year
- ATHA N/A
- MITQ N/A
- P/E Ratio
- ATHA N/A
- MITQ N/A
- Revenue Growth
- ATHA N/A
- MITQ N/A
- 52 Week Low
- ATHA $2.20
- MITQ $0.50
- 52 Week High
- ATHA $8.26
- MITQ $1.66
- Technical
- Relative Strength Index (RSI)
- ATHA 63.70
- MITQ 38.19
- Support Level
- ATHA $3.61
- MITQ $0.90
- Resistance Level
- ATHA $4.04
- MITQ $1.07
- Average True Range (ATR)
- ATHA 0.25
- MITQ 0.08
- MACD
- ATHA -0.16
- MITQ -0.03
- Stochastic Oscillator
- ATHA 20.92
- MITQ 1.33
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.